Home › NDC Lookup › RxCUI directory › RxCUI 2109233

Tafenoquine 150 MG Oral Tablet — RxCUI 2109233

RxNorm drug concept · Semantic clinical drug
RxCUI 2109233 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2109233
Official nameTafenoquine 150 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known astafenoquine (as tafenoquine succinate) 150 MG Oral Tablet
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Tafenoquine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • You're right that both contain tafenoquine, but they're approved for very different purposes. Arakoda (and Kodatef) are for preventing malaria when you're traveling to or living in...
  • What's the difference between Krintafel and Arakoda — they both seem to be the same drug?
  • That test checks for something called G6PD deficiency — a genetic condition where your red blood cells lack an enzyme they need to stay healthy under certain stresses. Tafenoquine...
  • Why do I have to get a blood test before taking this medication?
📖 Read our full Tafenoquine guide →

🕸️ Concept Web — How Tafenoquine 150 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Tafenoquine 150 MG Oral Tablet RxCUI 2109233

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Tafenoquine 2054023
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Krintafel 2109234
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Tafenoquine Oral Tablet 2054095
    • Tafenoquine Oral Product 2054093
    • Tafenoquine Pill 2054094
    • Tafenoquine Oral Tablet [Krintafel] 2109236
    • Krintafel Oral Product 2109237
    • Krintafel Pill 2109238
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Tafenoquine 150 MG SCDC · 2109232
  • Tafenoquine Oral Tablet SCDF · 2054095
  • Tafenoquine Oral Product SCDG · 2054093
  • Tafenoquine Pill SCDG · 2054094

Brand-Name Concepts

  • Tafenoquine 150 MG Oral Tablet [Krintafel] SBD · 2109239
  • Tafenoquine 150 MG [Krintafel] SBDC · 2109235
  • Tafenoquine Oral Tablet [Krintafel] SBDF · 2109236
  • Krintafel Oral Product SBDG · 2109237
  • Krintafel Pill SBDG · 2109238
  • Krintafel BN · 2109234

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2109233 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00173-0889-39 2 TABLET, FILM COATED in 1 BOTTLE (0173-0889-39) Krintafel GlaxoSmithKline LLC 2019-01-22
Observed labelers: GlaxoSmithKline LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.